BIOMAT Database Logo BIOMAT Database Logo

[Streptomycin and isoniazid resistance of strains of Mycobacterium tuberculosis isolated in Catania]. 1969

A Placenti

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013307 Streptomycin An antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by inhibiting the initiation and elongation processes during protein synthesis. Estreptomicina CEPA,Estreptomicina Clariana,Estreptomicina Normon,Strepto-Fatol,Strepto-Hefa,Streptomycin Grünenthal,Streptomycin Sulfate,Streptomycin Sulfate (2:3) Salt,Streptomycin Sulphate,Streptomycine Panpharma,Strepto Fatol,Strepto Hefa
D014397 Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. Pulmonary Consumption,Pulmonary Phthisis,Pulmonary Tuberculoses,Pulmonary Tuberculosis,Tuberculoses, Pulmonary,Consumption, Pulmonary,Consumptions, Pulmonary,Phthises, Pulmonary,Phthisis, Pulmonary,Pulmonary Consumptions,Pulmonary Phthises

Related Publications

A Placenti
[Resistance of Mycobacterium tuberculosis to streptomycin and isoniazid].
January 1954, Tuberkuloza,
A Placenti
[Resistance to streptomycin of Mycobacterium strains isolated from tuberculosis patients].
December 1981, Problemy tuberkuleza,
A Placenti
[Streptomycin resistance in strains of Mycobacterium tuberculosis isolated in human clinical cases].
September 1950, Revista de tuberculosis del Uruguay,
A Placenti
Rifampicin and isoniazid resistance mutations in Mycobacterium tuberculosis strains isolated from patients in Kazakhstan.
October 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
A Placenti
Resistance to rifampicin and isoniazid in strains of Mycobacterium tuberculosis.
August 1981, Journal of clinical pathology,
A Placenti
[Effect of combined treatment with streptomycin, PAS and isoniazid on resistance of Mycobacterium tuberculosis to streptomycin and isoniazid].
January 1955, Higijena; casopis za higijenu, mikrobiologiju, epidemiologiju i sanitarnu tehniku,
A Placenti
In silico analyses of isoniazid and streptomycin resistance-associated mutations in Mycobacterium tuberculosis.
January 2023, Computational and structural biotechnology journal,
A Placenti
Analysis of isoniazid, streptomycin and ethambutol resistance in Mycobacterium tuberculosis isolates from Morocco.
May 2009, Journal of infection in developing countries,
A Placenti
[Sensitivity and vitality of streptomycin-resistant strains of Mycobacterium tuberculosis as compared with isoniazid].
July 1953, Annales de l'Institut Pasteur,
A Placenti
[Molecular mechanisms of mycobacterium tuberculosis strains resistance to rifampicin and isoniazid].
January 2000, Problemy tuberkuleza,
Copied contents to your clipboard!